Line 130: | Line 130: | ||
</div> | </div> | ||
+ | <div class="container"> | ||
+ | |||
<hr style="height:2px;border:none;color:#333;background-color:#333;" > | <hr style="height:2px;border:none;color:#333;background-color:#333;" > | ||
<div class="row"> | <div class="row"> | ||
− | <video class="responsive-video center-margin" style="width: 100%; padding: 30px"> | + | <video class="responsive-video center-margin" style="width: 100%; padding: 30px" controls> |
− | <source src="https://static.igem.org/mediawiki/2018/7/77/T--EPFL--iGEM_2018_video.mp4" type="video/mp4" | + | <source src="https://static.igem.org/mediawiki/2018/7/77/T--EPFL--iGEM_2018_video.mp4" type="video/mp4" > |
</video> | </video> | ||
</div> | </div> | ||
+ | |||
+ | |||
+ | </div> | ||
Revision as of 17:59, 17 October 2018
CAPOEIRA
Cancer Personalized Encapsulin Immunotherapy and Relapse Assay
Learn more about our projectWhat is CAPOEIRA ?
While Melanoma remains the deadliest form of skin cancer, immunotherapy approaches can harness our immune system to defeat it! Yet, current immuno-treatments suffer from high costs, limited accessibility, and poor specificity. Our project “CAPOEIRA”, named after the Brazilian self-defense martial-art, exploits the potential of synthetic biology to develop a personalized, cost-effective, and rapid production scheme for cancer vaccine and point-of-care relapse surveillance. First, a bioinformatic pipeline integrating state-of-the-art tools identifies our targets: melanoma neoantigens, the fingerprints of cancer cells. Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes. This encapsulin vaccine activates dendritic cells which trigger T-cells’ attack on the neoantigen-bearing cancer cells. Nevertheless, we don’t underestimate a defeated villain! To detect potential relapse, we combine techniques including dumbbell probes, rolling circle amplification, isothermal amplification, and CRISPR-Cas12a to detect circulating tumor miRNA and DNA. Ultimately, CAPOEIRA trains the immune system to fight back!
This is CAPOEIRA
Bioinformatics
First, a bioinformatic pipeline integrating state-of-the-art tools identifies our target: melonoma neoantigens, the fingerprints of cancer cells
Vaccine
Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes
Dendritic cell Activation
This encapsulin vaccine activates dendritic cells which trigger T-cell's attack on the neoantigen bearing cancer cells
Follow-up
Nevertheless, we don't underestimate a defeated villain! To detect potential relapse we use techniques like CRISPR-Cas12a to detect circulationg tumor miRNA and DNA